Webcast Announcement for Q3 2025 Financial Results
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a leading biotechnology firm specializing in innovative therapies for cancer treatment, is gearing up to share its financial results for the third quarter of 2025. The results will be released before the market opens, specifically on November 6, 2025.
Details of the Conference Call
On the day of the release, the management team will host a conference call accompanied by a live audio webcast. This informative session is scheduled to commence at 8:30 a.m. ET. Attendees will have the opportunity to listen in on the results and gain insights into the corporate strategies moving forward.
Accessing the Webcast
For those interested in joining the live or archived session, registration is required. Furthermore, details will be accessible through the Investors section of Iovance's official website. It's important to note that the archived recording will remain available for a full year, providing ample opportunity for review.
About Iovance Biotherapeutics
Iovance Biotherapeutics is committed to pioneering new treatment pathways through tumor infiltrating lymphocyte (TIL) therapies. The company aims to be at the forefront of developing effective solutions that leverage the human immune system to tackle cancer. Their noteworthy TIL platform has shown promising clinical outcomes for various solid tumors.
Innovations in Cell Therapy
One of Iovance's flagship products, Amtagvi, stands as the first FDA-approved T cell therapy tailored for specific solid tumor indications. The company continually invests in research aimed at enhancing cell therapies, with a focus on emerging technologies like gene-edited cell therapy.
Contact Information for Inquiries
For more details regarding the company or the upcoming webcast, interested parties can reach out via email. Investors can contact the Investor Relations team at IR@iovance.com. For media inquiries, the communication should be directed to PR@iovance.com. Both departments can be reached at 650-260-7120 ext. 150.
Frequently Asked Questions
When will Iovance release its Q3 2025 financial results?
The financial results will be released before the market opens on November 6, 2025.
How can I listen to the webcast?
The webcast can be accessed through the Investors section of the Iovance Biotherapeutics website after registration.
What is Amtagvi?
Amtagvi is the first FDA-approved T cell therapy specifically designed for solid tumor indications, representing a significant milestone in cancer treatment.
How can I inquire more about Iovance?
For inquiries, you may contact the Investor Relations team at IR@iovance.com or the media team at PR@iovance.com.
What sets Iovance apart in cancer therapy?
Iovance focuses on innovating TIL therapies that utilize the human immune system to combat various cancers, underpinned by promising clinical data and ongoing developments.
